NASDAQ · EQHealthcarePharmaceuticals

Equillium financials

$1.62−3.57%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$0.00$41.1M$36.1M$15.8M————
Gross profit$0.00$41.1M$36.1M$15.8M————
Gross margin—100.0%100.0%100.0%————
Operating income-$23.6M-$8.3M-$14.5M-$62.1M-$37.8M-$29.5M-$26.7M-$8.6M
Net income-$22.4M-$8.1M-$13.3M-$62.4M-$39.1M-$29.8M-$25.6M-$13.3M
Net margin—−19.6%−37.0%−396.1%————
Diluted EPS$-0.39$-0.23$-0.38$-1.85$-1.36$-1.46$-1.47$-1.09
EBITDA-$23.5M-$8.1M-$14.4M-$62.0M-$37.7M-$29.5M-$26.7M-$8.6M
Operating cash flow-$22.7M-$19.0M-$21.8M-$31.8M-$32.1M-$24.6M-$22.9M-$7.5M
Free cash flow-$22.8M-$19.1M-$21.8M-$32.1M-$32.1M-$24.8M-$23.0M-$7.6M
Diluted shares57.3M35.4M34.7M33.7M28.8M20.4M17.4M12.2M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$30.3M$18.1M$23.2M$59.1M$50.4M$24.0M
Short-term investments$0.00$4.5M$17.6M$11.9M$30.3M$58.2M
Total debt$0.00$0.00$0.00$9.0M$10.2M$9.9M
Total assets$31.9M$25.6M$50.5M$78.4M$85.4M$85.4M
Total liabilities$3.3M$6.5M$28.0M$46.5M$18.9M$15.6M
Shareholders' equity$28.6M$19.1M$22.6M$31.9M$66.5M$69.9M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology